SUSPECT ADVERSE REACTION REPORT

NI-Tolmar-TLM-2025-01407

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
		Day	Month	Year			Day	Month	Year	
JDQO	NICARAGUA	13	Sep	2017	7	Female	23	Apr	2025	

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data)

1) Whitish mucus discharge from vaginal area (Vaginal discharge (10046901), Vaginal discharge (10046901))
(01/May/2025 -) - Not Recovered/Not Resolved/Ongoing
2) 22.5 mg every 3 months, for the indication Central Precocious Puberty (Off label dosing (10074165), Off label use (10053762))
(23/Apr/2025 -) - Not Recovered/Not Resolved/Ongoing

- ☐ PATIENT DIED
- ☐ LIFE THREATENING
- ☐ INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION
- ☐ RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY
- ☐ CONGENITAL ANOMALY
- ☐ OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S)INFORMATION

14. SUSPECT DRUG(S)(include generic name)

1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(15211AUY; 15211BUY; UNK)

Cont..

20. DID EVENT ABATE AFTER STOPPING DRUG? ☐ YES ☐ NO ☑ NA

15. DAILY DOSE(S)

1) (22.5 milligram(s), 1 in 3 Month)

16. ROUTE(S) OF ADMINISTRATION

1) Subcutaneous

21. DID EVENT REAPPEAR AFTER REINTRODUCTION ☐ YES ☐ NO ☑ NA

(NA : Not Applicable)

17. INDICATION(S) FOR USE

1) Central Precocious Puberty [10073186 - Central precocious puberty]

18. THERAPY DATE(S) (from/to)	19. THERAPY DURATION
1) (23/Apr/2025 - Ongoing)	

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)

No concomitants used/reported

23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)

1) CENTRAL PRECOCIOUS PUBERTY (10073186, Central precocious puberty) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER

Name : Tolmar, Inc
701 Centre Avenue
Fort Collins, CO, 80526, UNITED STATES OF AMERICA
debbie.maierhofer@tolmar.comand+1-4129158447

Study Information
Study Name: NA
EudraCT Number:
Protocol No.: NA
Center No.:
Subject Id :

24.REPORT NULLIFIED	24b. MFR CONTROL NO.
☐ YES ☐ NO	NI-Tolmar-TLM-2025-01407
24c. DATE RECEIVED BY MANUFACTURER: 06/May/2025	24d. REPORT SOURCE: ☑ STUDY ☐ LITERATURE ☐ HEALTH PROFESSIONAL
DATE OF THIS REPORT: 17/May/2025	25a. REPORT TYPE: ☑ INITIAL ☐ FOLLOWUP

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

Event Description :

This study report from Nicaragua was received by Adium via the PSP Solutions (Patient Support Program) (NI-ADIUM-NI-0042-20250506) on 06-May-2025 from a consumer (non-healthcare professional) regarding a child of 07-year-old female patient who experienced non-serious events of ‘Whitish mucus coming out of vaginal area” (Vaginal discharge) and “22.5 mg every 3 months, for the indication Central Precocious Puberty" (Off label use) during Eligard (Leuprolide acetate) 22.5 milligram therapy for Central Precocious Puberty. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 07-May-2025.

The patient's medical history was unknown and current condition included Central Precocious Puberty.

Concomitant medications were unknown.

On 23-Apr-2025, the patient began receiving Eligard 22.5 mg, every 3 months, via subcutaneous route for Central Precocious Puberty (Lot number: 15211AUY; 15211BUY; UNK Expiration date: May-2026; UNK; UNK). On the same day the patient had Off label use.

On 01-May-2025, the patient experienced whitish mucus discharge from vaginal area. No further details were available.

Corrective treatment was not required.

Action taken with Eligard in response to the events was dose not changed. De-challenge and re-challenge were not applicable.

The outcome of vaginal discharge and off label use was not resolved.

The reporter did not assess the seriousness of vaginal discharge and off label use.

The reporter did not provide the causality of off label use while assessed the causality of vaginal discharge in relationship to Eligard and Eligard unspecified device as related.

No follow-up queries were raised.

Listedness:
Vaginal discharge>Eligard>Unlisted as per CCDS>07-Nov-2024
Vaginal discharge>Eligard>Unlisted as per USPI>Feb-2025
Vaginal discharge>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Vaginal discharge>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Off label use>Eligard>Unlisted as per CCDS>07-Nov-2024
Off label use>Eligard>Unlisted as per USPI>Feb-2025
Off label use>Eligard unspecified device>Unlisted as per USPI>Feb-2025
Off label use>Eligard>Unlisted as per Canadian monograph>02-Apr-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): This case is regarding a child 7-year-old female patient for had vaginal discharge (Whitish mucus discharge from vaginal area) and off label use (Off label use) was reported during 22.5 milligram Eligard therapy for precocious puberty. Tolmar assessed the reported events as non-serious since they did not meet the ICH seriousness criteria and are not IME events. The reported event off label use was considered as not related to Eligard as the event occurred with the product and not due to drug. Off label use is assessed as not related to device component of Eligard. Considering close temporal association with Eligard administration and lack of other information suggestive of other causal role the event vaginal discharge was assessed as related to Eligard (drug). Event vaginal discharge was assessed as not related to Eligard device component.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug	:	Eligard® (Leuprolide acetate)
Active Substance	:	1) Leuprolide acetate
Drug Characterization	:	Suspect
Form of Admin	:	1) Injection
Lot Number	:	1) 15211AUY; 15211BUY; UNK
Daily Dose	:	(22.5 milligram(s), 1 in 3 Month)
Route of Admin	:	1) Subcutaneous
Indications	:	1) Central Precocious Puberty [10073186 - Central precocious puberty]
Therapy Dates	:	1) From : 23/Apr/2025 To :Continuing
Action(s) Taken With Drug	:	Dose not changed

Continuation Sheet for CIOMS report

Causality

1) Whitish mucus discharge from vaginal area (Vaginal discharge - 10046901, Vaginal discharge - 10046901)
Causality as per reporter : Related
Causality as per Mfr : Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) 22.5 mg every 3 months, for the indication Central Precocious Puberty (Off label dosing - 10074165, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Whitish mucus discharge from vaginal area
CORE UnLabeled
2) 22.5 mg every 3 months, for the indication Central Precocious Puberty
CORE UnLabeled

2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) 15211AUY; 15211BUY; UNK
Indications : 1) Central Precocious Puberty [10073186 - Central precocious puberty]
Action(s) Taken With Drug : Not applicable

Causality

1) Whitish mucus discharge from vaginal area (Vaginal discharge - 10046901, Vaginal discharge - 10046901)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
2) 22.5 mg every 3 months, for the indication Central Precocious Puberty (Off label dosing - 10074165, Off label use - 10053762)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

1) Whitish mucus discharge from vaginal area
CORE
2) 22.5 mg every 3 months, for the indication Central Precocious Puberty
CORE

15. DAILY DOSE(S) (Continuation...)

Dosage Text :

Drug 1 :Eligard®

1) Expiration date: May-2026; UNK; UNK